1, M, 25 | patient’s choice | <1 | 1 | 3 | — | increase of vitreous opacities | pyrimethamine and prednisone | 20/50 | 20/20 | 21 | — |
2, M, 44 | patient’s choice | 2 | 2.5 | 6 | — | increase of vitreous opacities | pyrimethamine and prednisone | 20/60 | 20/20 | 20 | + (5) |
3, F, 24 | patient’s choice | <1 | 1 | 4 | — | — | — | 20/30 | 20/25 | 22 | + (6) |
4, M, 43 | patient’s choice | <1 | 3 | 8 | — | increase of vitreous opalcities | pyrimethamine and sulphadiazine | 20/60 | 20/20 | 20 | — |
5, F, 33 | patient’s choice | <1 | 1 | 3 | — | — | — | 20/30 | 20/20 | 20 | — |
6, M, 28 | intolerant to triple treatment
| 5 | 0.5 | 4 | — | — | prednisone | 20/200 | 20/25 | 21 | — |
7, F, 31 | progressive disease with triple treatment
| >8 | 6 | 7 | — | — | — | LP | LP
| 20 | — |
8, F, 29 | progressive disease with triple treatment
| >8 | 4 | 3 | — | — | — | CF | 20/200
| 21 | — |
9, M, 54 | progressive disease with triple treatment
| 8 | 2 | 4 | — | — | — | 20/60 | 20/25 | 23 | — |
10, F, 73 | intolerant to triple treatment
| 3 | 3 | 5 | — | — | — | HM | HM
| 20 | + (7) |
11, F, 69 | intolerant to triple treatment
| 2 | 1.5 | 4 | — | — | — | CF | 20/50 | 13 | — |